Redirecting to https://apnews.com/press-release/pr-newswire/kelun-biotech-announces-breakthrough-therapy-designation-granted-in-china-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-immunotherapy-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-nsclc-f57c316c86ea64acf5ce379228a1916c